Efficacy of intravitreal bevacizumab in the treatment of refractory central serous chorioretinopathy

The use of Intravitreal Bevacizumab, an anti-VEGF medication, for treating Refractory Central Serous Chorioretinopathy (CSCR), a condition where fluid accumulates under the retina, potentially leading to vision loss. Traditional treatment methods may not always be effective for CSCR, making it a challenging condition to treat. The document likely presents a case report detailing the use of Bevacizumab in a patient resistant to standard therapies, highlighting its potential efficacy in treating refractory CSCR.